Clinical Trials Directory

A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

The purpose of this study is to assess whether SD-101 cream (3% or 6%) is effective in treating the lesions in subjects with Simplex, Recessive Dystrophic, or Junctional Epidermolysis Bullosa.

Stanford is now accepting new patients for this trial.


  • drug : 3% SD-101 dermal cream
  • drug : Vehicle (0% SD-101)
  • drug : 6% SD-101 dermal cream

Phase: Phase 2


Ages Eligible For Study:

6 Months - N/A

Inclusion Criteria

- Informed Consent form signed by the subject or the subject's legal representative; if the subject is under the age of 18 but capable of providing assent, signed assent from the subject. - Subject (or caretaker) must be willing to comply with all protocol requirements. - Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. - Subjects must be 6 months of age and older. - Subjects must have 1 target wound within a prespecified size range at study entry - Target wound must be of at least a certain age

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Emily Gorell

Footer Links: